moderna goldman sachs

Moderna, Goldman Sachs

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Seeking Alpha on MSN · 2d

Moderna slips as Goldman Sachs downgrades on revenue outlook

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

Business Insider · 2d

Moderna downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance

Moderna (MRNA) Receives a Hold from Bernstein

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

1don MSN

Why Moderna (MRNA) Crashed on Wednesday?

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Moderna Stock Is Sliding Wednesday: Here's Why

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Meet the future leaders of Goldman Sachs' investment bank

Inside the careers, accomplishments, and clients of Goldman's new heads of investment banking: Kim Posnett, Matt McClure, and ...

New York Post3d

Goldman Sachs staffers fume over paltry bonuses after CEO David Solomon’s eye-popping $39M payout

Goldman Sachs staffers are griping about getting paltry bonuses — despite a massive raise given to CEO David Solomon after the bank posted its best earnings in three years, The Post has learned.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results